Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled trial of atogepant for prevention of episodic migraine in pediatric patients
2022-501100-94-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Atogepant with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly migraine days across the 12-week treatment period. Planned start Jul 2023; status: authorised.
02
Drugs
atogepant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2022-501100-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501100-94-00.